Skip to content

Dr. Annerose Allemon

Active
Private limited companyfounded 2022active for 4 yearsLange Leemstraat 385, 2018 Antwerpen, BelgiumKBO/BCE: BE 0792.439.124
Summary

Dr. Annerose Allemon has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €16,447 and a net result of -€2,443. Equity fluctuates too strongly from year to year to read a trend from it. Its solvency ranks better than 40% of 20,700 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Overview

Official details

Source: KBO
Status
Active since 13-10-2022 Normal situation
Activity
General medical practice NACE 86210
Establishment unit
2.339.032.066 2018 Antwerpen, since 13-10-2022
Financial year end
31 December
Peppol
Reachable since 04-11-2025

Board and ownership

Board
  • Allemon AnneroseDirector · since 13-10-2022

Financial position

91 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
< 0.1%
Annual accounts 2025
Gross margin
-€1,660
Loss
€2,443
Equity
€16,447
▼ 69.6%
Total assets
€32,468
▼ 45.3%
Turnover not published (micro format)
Score breakdownlowers riskSector: Human health activities (NACE 86)Liquidity: current ratio 1.97, cash €21,523Figures for financial year 2025 (filed on 08-07-2026)Size: total assets €32,468Show the evidence

Checked score

Score 2025
91 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 27% of micro companies in human health (NACE 86)
Financial strength · tick: 2024
Average
Solvency 76-24
equity 50.7% of total assets
Liquidity 75-25
short-term debt 49.3% · cash 66.3%
Profitability 9-91
return on assets -7.5%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,160 companies, NACE 86, micro)
Last 24 months 12-2024: < 0.1% 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: < 0.1%● unchanged vs 07-2025highest value 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025lowest value 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: < 0.1%● unchanged vs 07-2026 09-2026: < 0.1%● unchanged vs 08-2026 10-2026: < 0.1%● unchanged vs 09-2026 11-2026: < 0.1%● unchanged vs 10-2026
Credit of up to €1,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 1.97 (11.14 in 2024), above the usual 1.5. Short-term debt is 49.3% and cash 66.3% of total assets. 49.3% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 40% of them on solvency, 57% on liquidity, 3% on profitability and 9% on growth.

The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Five signals.
lowers riskneutral
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Liquidity: current ratio 1.97, cash €21,523
NBB · annual accounts
lowers risk · Figures for financial year 2025 (filed on 08-07-2026)
NBB · annual accounts
lowers risk · Size: total assets €32,468
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 08-07-2026, 23 days ahead of the deadline.
NBB · 4 filings
Deviation from the deadline
2025
23 days early
2024
18 days late
2023
30 days late
2022
31 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 4 accounts on average 14 days after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 25 August (3 of the last 4 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
02-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since incorporation in 2022.
KBO publications

Key points

  • Caution: Lower net result than 92% of companies in human healthsector median €60,156 · 20,687 companies -€2,443 View

Recent changes

  1. · Gazette deed IncorporationStarting capital €1,000
All 8 events

Comparable companies

These companies have the same main activity as Dr. Annerose Allemon: general medical practice (NACE 86210). They are comparable in size and age: total assets between €20,500 and €40,700, founded between 2021 and 2023.

CompanyTotal assetsGross margin
Dr. Annerose Allemon Antwerpen€32,468-€1,660
BM SANTE Walhain€30,498-€19,502
Dokter Anouk Tans Aarschot€32,431-€10,100
Dr. Karen Poels Genk€30,397€362
Docteur Rukiye BAS Saint-Nicolas€38,764-€11,024
Dr. Kato Van der Goten Zonhoven€40,735-€27,333
Dr. Sophie Bakkers Mechelen€20,494-€1,122
Full comparison

Key facts about Dr. Annerose Allemon

What is the company number of Dr. Annerose Allemon?
The company number of Dr. Annerose Allemon is 0792.439.124. The VAT number is the same number with BE in front: BE 0792.439.124.
Where is Dr. Annerose Allemon based?
The registered office is at Lange Leemstraat 385, 2018 Antwerpen.Company details
What does Dr. Annerose Allemon do?
According to the KBO register, the main activity is general medical practice (NACE 86210).
What is the legal form of Dr. Annerose Allemon?
The legal form of Dr. Annerose Allemon is Private limited company (BV).
When was Dr. Annerose Allemon founded?
Dr. Annerose Allemon was founded on 13-10-2022.
Is Dr. Annerose Allemon still active?
Yes, Dr. Annerose Allemon is an active enterprise in the KBO register.
What is the turnover of Dr. Annerose Allemon?
The annual accounts for financial year 2025 state no turnover. The micro format does not require it.Financials
Is Dr. Annerose Allemon profitable?
In financial year 2025, Dr. Annerose Allemon made a loss of €2,443.
Where can I find the annual accounts of Dr. Annerose Allemon?
Dr. Annerose Allemon filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Dr. Annerose Allemon due?
Dr. Annerose Allemon must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.